General aspects of anti-angiogenesis and cancer therapy

Theresa G. Zogakis; Steven K. Libutti

doi:10.1517/14712598.1.2.253

General aspects of anti-angiogenesis and cancer therapy

Theresa G. Zogakis, Steven K. Libutti

Surgery

Research output: Contribution to journal › Article › peer-review

48 Scopus citations

Abstract

Angiogenesis is the outgrowth of new vessels from pre-existing ones. Tumour growth and metastasis is dependent on angiogenesis and many stimulatory and inhibitory factors have been described which play an active role in this process. Inhibition of tumour neovasculature may be one strategy to inhibit tumour growth. Naturally occurring inhibitors of angiogenesis have been discovered and synthetic agents have been designed. Many of these inhibitors are currently being evaluated in clinical trials for the treatment of cancer. This review discusses the mechanism of action of these anti-angiogenics as well as a description of the clinical trials in which they are being evaluated. 2001 Ashley Publications Ltd Papers of special note have been highlighted as: • of interest •• of considerable interest.

Original language	English (US)
Pages (from-to)	253-275
Number of pages	23
Journal	Expert opinion on biological therapy
Volume	1
Issue number	2
DOIs	https://doi.org/10.1517/14712598.1.2.253
State	Published - Jan 1 2001

Keywords

Angiogenesis
Cancer therapy
Carboxyamido-triazole
Endostatin
IL-12
Matrix metalloproteinases
Sitramin
Thalidomide
VEGF

ASJC Scopus subject areas

Pharmacology
Drug Discovery
Clinical Biochemistry

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1517/14712598.1.2.253

Cite this

@article{7e189f9335464b028afd4aa0aa8c6380,

title = "General aspects of anti-angiogenesis and cancer therapy",

abstract = "Angiogenesis is the outgrowth of new vessels from pre-existing ones. Tumour growth and metastasis is dependent on angiogenesis and many stimulatory and inhibitory factors have been described which play an active role in this process. Inhibition of tumour neovasculature may be one strategy to inhibit tumour growth. Naturally occurring inhibitors of angiogenesis have been discovered and synthetic agents have been designed. Many of these inhibitors are currently being evaluated in clinical trials for the treatment of cancer. This review discusses the mechanism of action of these anti-angiogenics as well as a description of the clinical trials in which they are being evaluated. 2001 Ashley Publications Ltd Papers of special note have been highlighted as: • of interest •• of considerable interest.",

keywords = "Angiogenesis, Cancer therapy, Carboxyamido-triazole, Endostatin, IL-12, Matrix metalloproteinases, Sitramin, Thalidomide, VEGF",

author = "Zogakis, {Theresa G.} and Libutti, {Steven K.}",

year = "2001",

month = jan,

day = "1",

doi = "10.1517/14712598.1.2.253",

language = "English (US)",

volume = "1",

pages = "253--275",

journal = "Expert opinion on biological therapy",

issn = "1471-2598",

publisher = "Informa Healthcare",

number = "2",

}

TY - JOUR

T1 - General aspects of anti-angiogenesis and cancer therapy

AU - Zogakis, Theresa G.

AU - Libutti, Steven K.

PY - 2001/1/1

Y1 - 2001/1/1

N2 - Angiogenesis is the outgrowth of new vessels from pre-existing ones. Tumour growth and metastasis is dependent on angiogenesis and many stimulatory and inhibitory factors have been described which play an active role in this process. Inhibition of tumour neovasculature may be one strategy to inhibit tumour growth. Naturally occurring inhibitors of angiogenesis have been discovered and synthetic agents have been designed. Many of these inhibitors are currently being evaluated in clinical trials for the treatment of cancer. This review discusses the mechanism of action of these anti-angiogenics as well as a description of the clinical trials in which they are being evaluated. 2001 Ashley Publications Ltd Papers of special note have been highlighted as: • of interest •• of considerable interest.

AB - Angiogenesis is the outgrowth of new vessels from pre-existing ones. Tumour growth and metastasis is dependent on angiogenesis and many stimulatory and inhibitory factors have been described which play an active role in this process. Inhibition of tumour neovasculature may be one strategy to inhibit tumour growth. Naturally occurring inhibitors of angiogenesis have been discovered and synthetic agents have been designed. Many of these inhibitors are currently being evaluated in clinical trials for the treatment of cancer. This review discusses the mechanism of action of these anti-angiogenics as well as a description of the clinical trials in which they are being evaluated. 2001 Ashley Publications Ltd Papers of special note have been highlighted as: • of interest •• of considerable interest.

KW - Angiogenesis

KW - Cancer therapy

KW - Carboxyamido-triazole

KW - Endostatin

KW - IL-12

KW - Matrix metalloproteinases

KW - Sitramin

KW - Thalidomide

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=0035294634&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035294634&partnerID=8YFLogxK

U2 - 10.1517/14712598.1.2.253

DO - 10.1517/14712598.1.2.253

M3 - Article

C2 - 11727534

AN - SCOPUS:0035294634

SN - 1471-2598

VL - 1

SP - 253

EP - 275

JO - Expert opinion on biological therapy

JF - Expert opinion on biological therapy

IS - 2

ER -

General aspects of anti-angiogenesis and cancer therapy

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this